BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Aug 08, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Ponesimod: Phase IIb data

A double-blind, international Phase IIb trial in 464 patients with RRMS showed that once-daily oral ponesimod met the primary endpoint of significantly reducing the cumulative number of new active inflammatory lesions as measured by T1-weighted MRI brain scans at weeks 12, 16, 20 and 24 after initiation of treatment vs. placebo (p<0.0001 for the most effective dose). Actelion...

Read the full 270 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >